Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Reimbursement Decisions Focus Mostly On Cancer

Executive Summary

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

You may also be interested in...



Intercept Boosts NASH Commercial Potential Via NICE Rare Disease Move

With Gilead snapping at its heels in NASH, Intercept will be pleased with its product's positive reimbursement recommendation in the UK for rare disease PBC; physicians will have the opportunity to familiarize themselves with Intercept's offering.

Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition

Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.

NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel